Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
31.6M
-
Shares change
-
+5.22M
-
Total reported value, excl. options
-
$1.03B
-
Value change
-
+$170M
-
Number of buys
-
43
-
Number of sells
-
-13
-
Price
-
$32.69
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q3 2020
68 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q3 2020.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.6M shares
of 72.2M outstanding shares and own 43.81% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (4.44M shares), Matrix Capital Management Company, LP (3.82M shares), FMR LLC (2.86M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.66M shares), Redmile Group, LLC (2.43M shares), CITADEL ADVISORS LLC (1.69M shares), PRIMECAP MANAGEMENT CO/CA/ (1.38M shares), VANGUARD GROUP INC (1.13M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.11M shares), and PERCEPTIVE ADVISORS LLC (1.05M shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.